Harms outweigh benefits for women aged 70 and over in national breast cancer screening programs

March 21, 2014

Extending national breast cancer screening programmes to women over the age of 70 does not result in a decrease in the numbers of cancers detected at advanced stages, according to new research from The Netherlands.

Instead, researchers told the European Breast Cancer Conference that their findings suggest that extending screening programmes to older women results in a large proportion of women being over-treated, and at risk from the harmful effects of such treatment, because these women were more likely to die from other causes than from any tumours detected in the early stages of growth.

Dr Gerrit-Jan Liefers (MD, PhD), a surgical oncologist and head of the geriatric oncology research group at Leiden University Medical Centre (Leiden, The Netherlands), said: "For a screening programme to be effective, one would expect that the incidence of early stage breast cancer would increase while the incidence of advanced stage cancer would decrease because any cancer would have been detected at an earlier stage.

"However, when we investigated the effect of extending the screening programme in The Netherlands from age 69 to 75, we found that it had not led to a decrease in the rate of advanced breast cancers detected, while the numbers of early stage tumours strongly increased. This implies that the effect of screening in elderly women is limited and leads to a large proportion of over-diagnosis."

The Netherlands programme was extended in 1998 to include women up to the age of 75. Dr Liefers and his colleagues looked at results from The Netherlands Cancer Registry for 25,414 women aged between 70-75 who were diagnosed with breast cancer between 1995 and 2011.

They found that after the extension of the upper age limit, the incidence of early stage breast cancer (stages 0, I and II) increased significantly from 260 cases per 100,000 women in 1995 to up to 382 cases per 100,000 women in 2011. Meanwhile, the number of advanced stage breast cancers (stages III and IV) did not change significantly: in 1995 there were 59 cases detected per 100,000 women compared to 53 per 100,000 in 2011.

"In these more elderly women, other, competing causes of death are of major importance. Although surgery that is confined to removing just a small tumour (loco-regional treatment) is generally considered to be low risk, we have previously demonstrated that the proportion of patients who develop postoperative complications strongly increases with age and increasing numbers of other diseases or conditions that they may have. Furthermore, older patients are at risk from the adverse side-effects of adjuvant treatments such as hormone therapy or chemotherapy. Therefore, screening could result in over-treatment and consequently in decreased quality of life and ability to function in older breast cancer patients, without lowering the incidence of advanced stage breast cancer or deaths from the disease," he said.

"In upcoming decades, an increasing proportion of will be elderly and, therefore, the additional costs of treating over-diagnosed tumours could result in a tremendous increase in health expenditure, while no actual health benefits are being obtained. Since in older patients is mostly not evidence-based due to poor inclusion of older patients in clinical trials, we propose that studies investigating breast cancer treatment are much more important than breast cancer screening in this population and should be prioritised.

"Currently, the NHS Breast Cancer Screening Programme in the UK is undertaking a large randomised controlled trial in patients aged 71-73 in order to evaluate the effects of screening on breast cancer incidence and mortality. Until results of this trial become available, we suggest that the decision to participate in the screening programme should be personalised, for instance in discussions with primary care physicians, and be based on remaining life expectancy, the patients' ability to function in everyday life and their preferences.

"A prediction tool should be developed in order to estimate which women are at increased risk of breast cancer and should receive breast cancer screening, instead of screening the whole population. For example, an older woman with a long life expectancy who has certain risk factors for developing breast cancer could benefit from breast cancer screening. In contrast, an older woman with multiple other diseases or life-limiting conditions, and without any risk factors for , will only be at risk of over-diagnosis and overtreatment and may not benefit from screening."

Dr Hilary Dobson, chair of EBCC-9's national organising committee and who is Clinical Lead of the West of Scotland Breast Screening Service and the Lead Clinician of the West of Scotland Cancer Advisory Network (WoSCAN), commented: "These findings from The Netherlands are important when considering how best to offer an effective screening strategy to women aged 70 years and over. The authors conclude that the challenge of over-diagnosis poses a significant issue in this age range when screening is offered on a population basis and suggest a move towards a more personalised approach would be more appropriate. Continued scrutiny and analysis of other studies, for example, the piloting of an age extension to invitations for up to the age of 73 currently underway in the UK, will provide an important contribution to the discussion."

Explore further: Screening does not shift breast cancer to earlier stages

More information: Abstract no: O-406, "Breast cancer screening in older women". Friday 21 March, Management of screen detected cancer session, 08.45-10.15 hrs GMT, Hall 2.

Related Stories

Screening does not shift breast cancer to earlier stages

March 4, 2014
Screening for breast cancer appeared to have a very limited effect on the occurrence of serious and aggressive cancer cases. On the other hand, it appeared to detect many more early cancer cases, cases which would otherwise ...

Deaths from breast cancer fall in Europe

March 20, 2014
Improvements in treatment, as well as enhanced access to care, underlie the sustained decreases in breast cancer mortality seen in 30 European countries [1] from 1989 to 2010. But there are notable variations between different ...

Annual screening does not cut breast cancer deaths, Canadian study suggests

February 11, 2014
Annual screening in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care, concludes a 25-year study from Canada published in BMJ today.

Where are we with breast cancer in 2013?

March 19, 2014
The global burden of breast cancer remains immense in 2013, with over 1.6 million new cases being diagnosed annually. This burden has been increasing at a rate of 3.1% per year, and while the majority of new cases are diagnosed ...

Report: Breast cancer incidence rates converging among white and African-American women

October 1, 2013
Breast cancer incidence rates increased slightly among African American women from 2006 to 2010, bringing those rates closer to the historically higher rates among white women, according to a new analysis by American Cancer ...

Regular physical activity reduces breast cancer risk irrespective of age

March 20, 2014
Practising sport for more than an hour day reduces the risk of contracting breast cancer, and this applies to women of any age and any weight, and also unaffected by geographical location, according to research presented ...

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.